PFA
BIIB icon

Pathway Financial Advisors’s Biogen BIIB Stock Holding History

Pathway Financial Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-208
Closed -$60K – 130
2018
Q2 		$60K Hold
208
– – 0.04% 228
2018
Q1 		$57K Hold
208
– – 0.03% 226
2017
Q4 		$66K Buy
+208
New +$66.7K 0.04% 207

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Pathway Financial Advisors's BIIB Position: Q3 2018 in Review

Pathway Financial Advisors sold out of Biogen (BIIB) in Q3 2018, closing a stake of 208 shares — an estimated $60K sold.

Pathway Financial Advisors first reported a position in BIIB in Q4 2017 and held it in 3 quarters. The position peaked at $66K in Q4 2017. 1,146 funds tracked by Wall St. Rank hold BIIB as of Q3 2018.

  • Pathway Financial Advisors reported no remaining Biogen position as of Q3 2018 after selling out during the quarter.
  • Pathway Financial Advisors sold 208 Biogen shares in Q3 2018, an estimated $60K.
  • Pathway Financial Advisors first reported a position in Biogen in Q4 2017 and held it in 3 quarters.
  • Pathway Financial Advisors's Biogen position peaked at $66K in Q4 2017.
  • 1,146 funds tracked by Wall St. Rank held Biogen as of Q3 2018.

Based on Pathway Financial Advisors's 13F filing for Q3 2018, filed 16 Jan 2019.